Research programme: nanoparticle viral therapies - NanoViricides

Drug Profile

Research programme: nanoparticle viral therapies - NanoViricides

Alternative Names: Anti-HCV nanoviricide (HepCCide); Antiviral nanomedicines - NanoViricides; AviFluCide I; AviFluCide-HP; EbolaCide; EkC-Cide; EKC-Cide-I; EkCCide; FluCide; FluCide anti-influenza drug candidates - NanoViricides; FluCide I; FluCide-HP; HepCCide; HerpeCide; Herpicide; Herpicide-I; HIVCide; HivCide-I; HiviCide I; HiviCide-II; Injectable FluCide™; MERS-CoV therapeutic - NanoViricides; Nanoviricides®; NV-INF-1; NV-INF-2; Oral FluCide™ anti-influenza drug candidates - NanoViricides; RabiCide-I

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoViricides
  • Developer Baylor College of Medicine; NanoViricides; Southern Research Institute; SUNY Upstate Medical University; United States Army Medical Research Institute of Infectious Diseases; University of California at San Francisco; University of Pittsburgh; University of Wisconsin-Madison
  • Class Antivirals; Polymers; Viral fusion proteins
  • Mechanism of Action CCR5 receptor modulators; CD4 antigen modulators; CXCR4 receptor modulators; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dendritic keratitis; Ebola virus infections; Herpes simplex virus infections; HIV-1 infections; Infectious keratoconjunctivitis; Influenza virus infections; Rabies
  • Research Middle East respiratory syndrome coronavirus; Varicella zoster virus infections; Zika virus infection
  • Suspended Hepatitis C

Most Recent Events

  • 29 Sep 2017 Nanoviricides plans a phase I trial for HerpiCide™ programme
  • 16 Feb 2017 Early research in Varicella zoster virus infections in USA (Topical)
  • 31 Oct 2016 Nanoviricides and the SUNY Upstate Medical University enter into a collaboration to evaluate Nanoviricides' drug candidates in USA for Herpes simplex virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top